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New Insights into the Role of Androgens in Wolffian
Duct Stabilization in Male and Female Rodents
Michelle Welsh, Richard M. Sharpe, Marion Walker, Lee B. Smith,
and Philippa T. K. Saunders
Human Reproductive Sciences Unit, Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom
Androgen-mediated wolffian duct (WD) development is programmed between embryonic d 15.5
(e15.5) and 17.5 in male rats, and WD differentiation has been shown to be more susceptible to
reducedandrogenaction than is its initial stabilization.We investigated regulationof these events
by comparing fetalWDdevelopment at e15.5–postnatal d0 inmale and female androgen receptor
knockoutmice, and in rats treated frome14.5with flutamide (100mg/kg/d) plus di-n(butyl) phtha-
late (500 mg/kg/d) to block both androgen action and production, testosterone propionate
(20mg/kg/d) tomasculinize females, or vehicle control. In normal females,WD regression occurred
bye15.5 inmiceande18.5 in rats, associatedwitha lackofepithelial cell proliferationand increased
apoptosis, disintegrationof thebasementmembrane, and reduced epithelial cell height. Exposure
to testosteronemasculinized female rats including stabilizationandpartial differentiationofWDs.
Genetic or chemical ablation of androgen action in males preventedmasculinization and induced
WDregressionvia similarprocesses to those innormal females, except this occurred2–3d later than
in females. These findings provide the first evidence that androgens may not be the only factor
involved indeterminingWDfate.Other factorsmaypromote survival of theWDinmalesoractively
promote WD regression in females, suggesting sexually dimorphic differences in the prepro-
grammed setup of the WD. (Endocrinology 150: 2472–2480, 2009)
Before sex determination and differentiation of gonads intoeither testes or ovaries, male and female fetuses have an
identical urogenital system (1, 2), with reproductive target tis-
sues reported to express theandrogen receptor (AR) inboth sexes
(3). After functional differentiation of the fetal testis, the Leydig
cells secrete testosterone (2, 4, 5). Testicular androgens bind to
and activate the AR, which in turn drives masculinization, crit-
ical features of which include stabilization and differentiation of
thewolffianduct (WD), prostate formation and expansionof the
anogenital distance (AGD) (2, 6–8). Once the WD has been
stabilized in males, it differentiates to form its adult derivatives,
the epididymis, vas deferens, and seminal vesicles (9–11). Con-
versely, in females theovarydoes not produce testosterone at this
time, and so the WD degenerates (1, 2, 6). This is thought to be
due to the lack of available ligand in the female rather than an
inability to respond to androgens (12).
Previous studies have investigated androgen-dependent dif-
ferentiation of the reproductive tract by examining the impact of
blocking fetal androgen action either genetically (13) or chem-
ically, using AR antagonists such as flutamide (11, 14) or com-
pounds such as Di(n-butyl) phthalate (DBP), which reduces fetal
testicular testosterone production (15–18). Recently, we discov-
ered that the critical window for androgen action in ensuring
both initialWD stabilization and later differentiation is between
embryonic d 15.5 (e15.5) and e17.5 in rats (14). This window is
just after theonset of fetal testicular testosteroneproduction, and
surprisingly several days either before the peak in testicular tes-
tosterone levelsper testis (4, 19)ormorphological differentiation
of the WD (11, 14). These studies demonstrated that WD dif-
ferentiation is more susceptible to reduced androgen action than
is its initial stabilization (11, 14). However, in these studies it is
possible that the treatment regime may not block AR-mediated
signaling events completely because the flutamide was adminis-
tered to the pregnantmother rather than directly to the fetus (11,
14), and endogenous testosterone levels are high in male fetuses
during the last week of gestation, especially in the testis andWD
(20). Therefore, it is possible thatWD stabilizationmay proceed
in the presence of lower levels of androgen action than that re-
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quired for its differentiation or that WD stabilization and dif-
ferentiation may be regulated by different mechanisms and/or
additional factors.
The present study sought to gain additional insight into WD
development by comparing normal WD stabilization in males
with WD regression in males in which androgen action was
chemically or genetically ablated and with females in which an-
drogens are naturally absent (2, 21). Furthermore, because fetal
urogenital tissues in the female express AR (3), we administered
exogenous testosterone to pregnant dams to “masculinize” their
female fetuses and examined the impact on WD stabilization/
development. We demonstrate that exogenous testosterone can
rescue and partially differentiate the WD in females, but, sur-
prisingly, ablation of androgen action in males leads to WD
regression 2–3 d later than in normal females.
Materials and Methods
In vivo rat studies
Wistar ratswere bred andmaintained in our ownanimal house under
standard conditions according to United Kingdom Home Office guide-
lines. Animals had access ad libitum towater and a soy-free breeding diet
(SDS, Dundee, UK). Time matings were established, and the presence of
a vaginal plug was taken as evidence of mating; this was defined as e0.5.
A total of 38pregnant damswere used for this studywithdams randomly
allocated to treatment groups. The natural regression studies were un-
dertaken in rats that had not been dosed with any treatment (n  9
litters).Other“treated”damsweredoseddailybetween0830and1000h
according tomaternal bodyweightwith: 1) testosterone propionate (TP)
at 20 mg/kg1 by sc injection in 0.4 ml/kg1 corn oil between e14.5 and
21.5 (n  10); or 2) DBP (500 mg/kg1) plus flutamide (100 mg/kg1)
(DBP plus F) by oral gavage in 1 ml/kg1 corn oil/2.5% dimethylsulf-
oxide between e14.5 and 21.5 (n  6 litters). Control dams (n  10
litters) were gavaged daily with the vehicle alone (1 ml/kg1 corn oil/
2.5% dimethylsulfoxide). Dams were dosed from e14.5 until the day
before cull. This window of exposure was selected to begin before the
onset of androgen production at e15.5 (4) and encompass the period of
fetal male reproductive development (e15.5–e21.5) (12). The doses of
flutamide and DBP were selected based on results previously reported,
highlighting their impact on male reproductive tract development (11,
22–24). The dose of TP selected was based on previous results showing
that doses above 1 mg TP (per rat) increased female fetal testosterone by
80% and increased female AGD without a high incidence of toxicolog-
ical effects (25). However, it is worth noting that TP is aromatizable, so
it is possible that some of the testosterone injected into the pregnant dam
will be converted into estradiol in the placenta (26), therefore, the exact
dose of testosterone that the fetus was exposed to cannot be defined.
Dams were checked daily for signs of toxicity, and dam weights were
recorded daily throughout the dosing regime.Male and female offspring
were subsequently evaluated during fetal life (e16.5–e21.5). Dams were
killed by inhalation of carbon dioxide and subsequent cervical disloca-
tion, and pups were recovered, decapitated, and placed in ice-cold PBS
(Sigma-Aldrich Corp., St. Louis, MO).
Before recovery of reproductive tracts, AGD was measured in fetal
(e21.5) males and females using digital calipers (Faithfull Tools, Kent,
UK) because AGD reflects the degree of masculinization of the animal
(reviewed in Ref. 7). The urogenital sinus (prospective prostate) and
gonads with the attached WDs were collected from control and treated
male and female fetuses, examined with a Leica MZ6 dissecting micro-
scope, and photographed using a Leica ICA camera (LeicaMicrosystems
GmbH, Wetzlar, Germany) to enable gross morphological evaluation.
Androgen receptor knockout (ARKO) mice
Female mice heterozygous for the X-linked hypoxanthine phospho-
ribosyltransferase-Cre transgene (27) were mated to male ARflox mice
(28) to produce females carrying one deleted allele and one wild-type
(WT) allele of the X-linked AR gene. These females were subsequently
mated to produce ARKO males and control littermates. Genotype was
established by PCR. The presence of the Cre recombinase transgene was
determined using primers GATCGCTGCCAGGATATACG and AG-
GCCAGGTATCTCTGACCA. Genotyping of ARKO mice was com-
pleted using primers GCTGATCATAGGCCTCTCTC and TGCCCT-
GAAAGCAGTCCTCT, which generate amplicons of 1072 and 680 bp
for WT and ARKO, respectively.
Dams (n  9) were killed by inhalation of carbon dioxide and sub-
sequent cervical dislocation, and pups were recovered, decapitated, and
placed in ice-cold PBS. Gonads with the attached WDs were collected
frommale and female fetuses (e15.5 and e16.5) or from neonates on day
of birth [postnatal d 0 (pnd0), n 2 litters], and examined with a Leica
MZ6dissectingmicroscope andphotographedusing aLeica ICAcamera
to enable gross morphological evaluation.
Tissue fixation
WDswere fixed in Bouin’s for 1 h before being transferred into 70%
ethanol and processed for 17.5 h in an automated Leica TP1050 pro-
cessor.WDswere then embedded in paraffinwax, sectioned (5m), and
floated onto slides coated with 2% 3-aminopropyltriethoxy-silane (Sig-
ma-Aldrich) and dried overnight at 50 C before histological analysis (see
below). Representative WDs from at least three animals from at least
three litters from the aforementioned groups of rats and mice were sub-
sequently used for the studies detailed below. Histological analysis was
performed on WD sections stained with hematoxylin and eosin, using
standard protocols, and careful note was taken of any histological
abnormalities.
Immunohistochemistry
Immunohistochemistry was performed on WDs recovered from
mouse and rat fetuses using previously published standard avidin-per-
oxidase protocols and citrate antigen retrieval (11). WDs were stained
for AR (1:50; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), laminin
(1:100; Abcam plc, Cambridge, UK), cleaved caspase 3 (1:200; Cell Sig-
naling Technologies, Beverly, MA), phospho-histone H3 (1:1000; Up-
state Biotechnology Inc., Lake Placid, NY), and pan-cytokeratin (1:200;
Sigma-Aldrich). Cellular sites of expression were determined and slides
photographed using a Provis AX70 (Olympus Optical, London, UK)
microscope fitted with a Canon DS6031 camera (Canon Europe, Am-
sterdam, The Netherlands). To ensure reproducibility of results and al-
lowaccurate comparisonof immunostainingbetweengroups, sectionsof
WDs from control and treated/knockout animals were processed in par-
allel on at least three occasions; sections of WDs from at least three
animals in each group were run on each occasion. Appropriate negative
controls were included, whereby the primary antibody was replaced by
normal goat serum alone, to ensure that any staining observed was spe-
cific; none of the antibodies used showed other than minor nonspecific
staining.
Epithelial cell height analysis
WD sections were immunostained for pan-cytokeratin as detailed
previously to label clearly all epithelial cells. Sections were viewed using
an Olympus BH-2 microscope fitted with a Prior automatic stage (Prior
Scientific Instruments Ltd., Cambridge, UK). Image-Pro Plus version
4.5.1 with Stereologer-Pro 5 plug-in software (Media Cybernetics UK,
Wokingham, Berkshire, UK) was used to measure epithelial cell height.
Using a63 objective, WD epithelial cell height was measured in every
fifth epithelial cell per section. Only epithelial cells in which the nucleus
could be clearly identified were measured, thus excluding from analysis
any epithelial cells from treatment/knockout animals that were severely
flattened or degrading.
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Statistical analysis
Values have been expressed as means  SEM. Data were analyzed
using Fisher’s exact test (incidence of prostates and WDs) or one-way
ANOVA(AGDand epithelial cell height), usingGraphPadPrismversion
4 (GraphPad Software Inc., San Diego, CA).
Results
Effectiveness of the rat models in manipulating
masculinization endpoints (AGD and prostate formation)
Both AGD and prostate formation depend upon androgen
action (8, 29, 30), and are commonly used markers of fetal an-
drogen action. At e21.5, AGD in fetalmale rats is approximately
twice as long as in females, and at this age, elaborate prostatic
bud branching can be identified in control male rat fetuses but
not in females (Fig. 1). Fetal exposure to exogenous testosterone
increased female AGD to a length comparable to control males
and induced elaborate prostatic bud branching in female fetuses
at e21.5. In contrast, masculinization was prevented at e21.5 in
male rat fetuses exposed to DBP in combination with flutamide
(DBP plus F), as evidenced by reduction of AGD to a length
comparable to that in control females and complete prevention
of prostatic bud branching (Fig. 1).
Timing of normal WD development in male and female
rat fetuses
At e16.5–e17.5, a patentWDwas readily identified in female
rats lying medial to the mu¨llerian duct (MD): this WD began to
regress in a cranio-caudal direction and, by e18.5, was barely
identifiable upongross examination (Fig. 2),with apatent lumen
only visible at the caudal end. Conversely in males, the WD
remained a simple straight duct throughout this periodwhile the
MD regressed between e17.5–e18.5 (Fig. 2). Therefore, a de-
tailed investigation of WD regression and stabilization was un-
dertaken in all subsequent studies at e18.5, when the WD has
almost completely regressed in control females. Any experimen-
FIG. 2. Timing of WD development in representative male and female rat
fetuses at e17.5–e21.5. A, Note that at e17.5, the WD (arrow) is obvious in
females, lying medial to the MD (arrowhead). At e18.5 the WD has almost
completely regressed in females and is completely absent at e21.5. Exposure to
testosterone prevented WD regression in females, with the WD evident at both
e18.5 and e21.5 (arrow). At e18.5 the WD is a simple straight duct in males, but
at e21.5 the future epididymal segment has differentiated and become highly
coiled. The WD is present and looks morphologically normal at e18.5 in males
exposed to DBP plus F, but at e21.5 the WD has almost completely degenerated
with little patent lumen apparent, leaving a remnant mesenchymal-like structure
(*). The presence or absence of WDs in male and female fetuses was quantified
at e16.5–e21.5 (B), and is summarized in Table 1. All images are at the same
magnification (25). O, Ovary; T, testis. **, P  0.001, compared with age-
matched control males; a, P  0.001 compared with age-matched control
females. N/D, Not determined.
FIG. 1. Effectiveness of the treatments in manipulating masculinization
endpoints (AGD and prostate formation). Quantification of AGD and the
presence of a prostate in male and female fetuses from control (solid bars), DBP
plus F-exposed (striped bars), and testosterone (T)-exposed (checkered bars)
litters at e21.5. Note that AGD was significantly smaller in control female fetuses
than in males. Exposure to testosterone completely masculinized AGD in females
but had no effect on male AGD. Conversely, exposure to DBP plus F reduced
male AGD to female levels but had no effect on female AGD. Testosterone
exposure induced prostate formation in females, whereas exposure to DBP plus F
prevented prostate formation in males. ***, P  0.001, compared with control
males. Values are means  SEM.
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tal perturbation of the timing ofWDregression should be readily
identifiable at this age.
Ability of exogenous testosterone to stabilize and
differentiate the WD in female rats
At e18.5 and e21.5,WDswere present in all females exposed
in utero to testosterone, with 87%of them showing some degree
of coiling at e21.5; however, this coiling was less extensive than
that observed inWDs of control, age-matched males (Fig. 2 and
Table 1). These “stabilized”WDs in females persisted into adult-
hoodbutneverdevelopedas fully as the equivalent“epididymal”
organ in males (data not shown). Exposure to flutamide (100
mg/kg1) in combination with testosterone (20 mg/kg1) pre-
ventedWDstabilization in females, and, in this treatment group,
no WDs were identified in any female examined at e21.5 (data
not shown). These data confirm that females can respond to
androgens, and that testosterone alone can stabilize andpartially
differentiate the WD in females; this experimental masculiniza-
tion can be prevented by flutamide exposure. There was no ob-
vious effect of exogenous testosterone exposure on the gross
morphology of WDs in males at either e18.5 or e21.5, i.e. epi-
didymal coiling was not initiated any earlier or to any greater
extent than in control males (data not shown).
Impact on WD development of ablating androgen action
in male rats
Treatment with DBP plus F did not induce any gross WD
abnormalities in males at e18.5 (Fig. 2), and a complete and
patentWDwasobserved inall e18.5 fetuses examined (Fig. 2and
Table 1). In contrast, at this age the WD in control females had
completely regressed (Fig. 2). However, exposure to DBP plus F
resulted in the loss of allWD structures in 25%ofmales at e20.5
(data not shown) and in all male fetuses by e21.5 (Fig. 2 and
Table 1), with a patent lumen only apparent in the residual caput
segment of the WD, whereas the rest of the WD appeared as a
remnant mesenchymal-like structure (Fig. 2). Thus, although
DBP plus F resulted in the absence of the WD, the timing of its
regression (e20.5–e21.5) was 2–3 d later than occurred in nor-
mal females (e18.5) (Table 1).
WD regression in ARKO mice
In WT male mice, the WD could clearly be identified as a
simple straight duct at e15.5, but by e16.5, some coiling could be
identified in the future caput epididymis (Fig. 3). By the day of
birth (pnd0), the future epididymiswashighly coiled.Conversely
in WT females, the WD had regressed almost completely by
e15.5, with a patent lumen only visible at the caudal end (Fig. 3),
lying medial to theMD. In contrast, in ARKOmales a complete
WD could still be readily identified at e15.5 (Fig. 3 and Table 1).
By e16.5, the WD had started to regress in ARKO males, but a
patent lumen could still be identified in the caput by gross in-
spection (Fig. 3). At pnd0 the WD had almost completely re-
gressed, with a patent lumen only apparent in the residual caput
segment of the WD, whereas the rest of the WD appeared as a
remnant mesenchymal-like structure. Therefore, complete abla-
tion of AR signaling in ARKOmice resulted in an absence of the
WD by birth, but its regression (around e16.5) occurred at ap-
proximately 2 d later than occurred in normal females (Table 1).
Apoptosis, proliferation, and morphology of the
epithelium in WDs from male and female fetuses
Analysis of apoptosis, cell proliferation, and epithelial degen-
erationwas undertaken inWDs recovered frommale and female
fetuses because these cellular processes have been suggested to
TABLE 1. Summary of the incidence of WD regression and the histological processes involved
WD regressed
Proliferation
BM interrupted Epithelial height reducedApoptosis epithelia Epithelia Stroma
Mouse
e15.5
WT male 0% (0/5) X   X X
ARKO male 0% (0/5) X   X X
Female 100% (6/6) N/A N/A v N/A N/A
e16.5
WT male 0% (0/16) X   X X
ARKO male 30% (3/10) X   X X
Female 100% (17/17) N/A N/A N/A N/A N/A
Rat
e18.5
Control male 0% (0/17) X   X X
DBP plus F male 0% (0/32) X   X X
Control female 82% (18/22)  X   
T female 0% (0/19) X   X X
e21.5
Control male 0% (0/37) X   X X
DBP plus F male 100% (35/35)  X   
Control female 100% (32/32)  X X  
T female 0% (0/30) X   X X
Values are the number of animals the WD regressed in, out of the total number of animals examined. Bold values are different from age-matched control males.
Non-bold values are the same as age-matched control males.
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play a role in MD regression in males (5, 31–33) and in causing
WD abnormalities in males exposed to antiandrogens during
fetal life (11, 14). These results are summarized in Table 1. Note
that in control females, little epithelium was present in the WD,
therefore, the images shown in this paper were selected to show
the phenotype of any persisting epithelium.
Apoptotic cells (positively immunostained for cleaved
caspase 3) were noted in the epithelium of the WD from female
rats at e17.5 (datanot shown) and in the remnantWDepithelium
at e18.5 (Fig. 4A); this was in contrast to age-matched control
males in which the WDs were immunonegative for cleaved
caspase 3. Similarly, apoptotic cellswere rarely detected in either
the epithelium or stroma of WDs from testosterone-exposed fe-
male fetuses at e18.5 (Fig. 4A) or 21.5 (data not shown). Apo-
ptosis was not apparent in WDs from DBP plus F-exposed male
fetuses at e18.5 (Fig. 4A) or at 21.5 (data not shown), or in
ARKOmalemice at e15.5 or 16.5, although it is emphasized that
by e21.5 in rats and e16.5 in mice, very little epithelium was
present in the WDs of these males. Because epithelial cell apo-
ptosis was evident in the regressing WD from females but not in
the WD of DBP plus F-exposed or ARKO males, this highlights
a potential difference in the cellular mechanisms of WD degen-
eration in each of these models.
Immunostaining for phospho-histone H3 showed that mi-
totic cells were present in the stroma surrounding the regressing
WD from e16.5–e18.5 females, but they were rarely detected in
the epithelium (data not shown) (summarized in Table 1). This
was in contrast to control males in which mitotic cells were ev-
ident in both the stromal and epithelial cell compartments of the
FIG. 3. Timing of WD development/regression in ARKO mice compared with WT
males and females at e15.5–pnd0. A, In WT males the WD (arrow) was clearly
identified at all ages examined (e15.5–pnd0). However, in WT females the WD
had almost completely regressed by e15.5, with a patent lumen only visible at
the caudal end (arrow), lying medial to the MD (arrowhead). The WD was
completely absent in females at e16.5 and pnd0. Conversely, in ARKO males a
complete WD could still be readily identified at e15.5 (arrow). By e16.5 the WD
had started to regress in ARKO males, but a patent lumen could still be identified
at the caput (arrow). At pnd0 the WD had almost completely regressed in ARKO
males, with a patent lumen only apparent in the residual caput segment of the
WD. The presence or absence of WDs in male and female fetuses was quantified
at e15.5–pnd0 (B) and is summarized in Table 1. All images are at the same
magnification (25). KO, Knockout; O, ovary; T, testis. ***, P  0.001.
FIG. 4. Effects of androgen action on apoptosis and the basement membrane in
male and female WDs from rats (e18.5) and mice (e16.5). A, Representative
images of apoptotic cells (immunopositive for cleaved caspase 3, brown staining)
in WD from male and female fetuses. Apoptosis is evident in the epithelium of
WDs from control females (arrow) but is rarely seen at e18.5 in WDs from control
or DBP plus F-exposed male rats or from testosterone (T)-exposed female rats.
Conversely, apoptotic cells are evident in the epithelium of the MD in control
males (arrowhead). Apoptosis is rarely seen at e16.5 in WDs from WT or ARKO
male mice. Occasional apoptotic cells can be seen in the residual epithelium still
remaining in WDs from female mice at e16.5 (arrow). B, Demarcation of the
basement membrane in WDs from male and female fetuses by immunostaining
for laminin (brown) in the basement membrane. Note that laminin forms a
defined “ring” at the basement membrane in control male WDs (arrow) and also
in WDs from DBP plus F-exposed male rats, from ARKO male mice, and from
testosterone-exposed female rats. Conversely, in normal females the WD
basement membrane is disrupted and the epithelium flattened, leaving patches
of diffuse laminin expression (arrowhead). Note that laminin forms a defined
“ring” at the basement membrane of the MD in control females. Scale bar, 100 m.
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WDat all ages examined (e16.5–e21.5, data not shown). Similar
patterns were seen in WT mice (data not shown). Mitotic cells
were noted in theWD epithelium and stroma at e18.5 and e21.5
(data not shown) in female rats exposed to exogenous testoster-
one. Phospho-histone H3 positive cells were still evident in both
the stromal and epithelial cell compartments of WDs from DBP
plus F-exposed male rats at e18.5 and in ARKO male mice at
e16.5 (data not shown). However, by e21.5 in DBP plus F-ex-
posed rats and pnd0 in ARKO male mice, mitotic cells were
rarely noted in the residual epithelium of WDs but could still be
identified in the remnant stromal compartment (data not
shown). Therefore, cell proliferation was evident in the stromal
compartment ofWDs from bothmales and females in all models
examined, but variationwas noted in epithelial cell proliferation
between males and females (Table 1).
Immunostaining for laminin highlighted that the basement
membrane around the WD epithelium was interrupted and
incomplete in the regressing WD from control female rats at
e16.5 compared with the defined “ring” of laminin evident in
the basement membrane of WDs from control male rats at
e16.5–e21.5 (data not shown) (Table 1). By e18.5 the WD in
control female rats had almost completely regressed, leaving
only patches of laminin staining where the epithelium had
once been (Fig. 4B). Similar patterns were seen in WT mice.
Exposure of rats to exogenous testosterone prevented this
interruption to the basement membrane and resulted in a de-
fined “ring” of laminin in the basement membrane in WDs
from females at e18.5 (Fig. 4B) and e21.5 (data not shown).
In contrast to normal females, exposure of male rats to DBP
plus F did not interrupt laminin expression in the basement
membrane of WDs at e18.5 (Fig. 4B), but by e21.5, laminin
expression was poorly defined and was often absent (data not
shown). Similarly, in e16.5 ARKOmale mice, laminin expres-
sion in the basementmembranewas comparable to that inWT
littermates (Fig. 4B), but by pnd0 this laminin “ring” was
absent (data not shown).
Epithelial abnormalities were noted in the regressing WD of
control females at all ages examined (e16.5–e18.5) in comparison
to age-matched control male WDs. These included an apparent
reduction in epithelial cell height and a narrowing or absence of a
patent lumen at e18.5 (Fig. 5A). Exposure to exogenous testoster-
onepreventedtheseabnormalitiesbecause theWDepitheliumfrom
exposed female fetuseswashistologically comparable toWDs from
age-matched control males at e18.5 (Fig. 5A) and e21.5 (data not
shown). Exposure to DBP plus F did not result in reduced
height of theWD epithelium inmale fetuses at e18.5 (Fig. 5A),
but by e21.5 the majority of these animals had very little
epithelium evident, especially distal to the caput; any epithe-
lium present was flattened with a grossly abnormal lumen
(data not shown). Similar patterns were noted in WDs from
male ARKO mice, whereby epithelial cell height was not re-
duced at e16.5, compared withWT littermates, and the lumen
was patent (Fig. 5B).However, by pnd0, epitheliumwas rarely
present in WDs from any ARKOmale mice (data not shown).
Quantitative measurement of epithelial cell height confirmed
these histological observations (Fig. 5, A and B). No WD ep-
ithelium was present in female mice to measure at e16.5.
Discussion
Various studies have shown that androgens play a critical role in
WD development (15, 17, 22, 34–36). The majority of studies
used experimental impairmentof fetal androgenactionwith sub-
sequent evaluationof themales postnatally anddemonstrated an
absence of WD-derived tissues. The interpretation from these
studies was that, in the absence of fetal androgen action, theWD
regressed in males at the same time as in age-matched (normal)
females. However, results from previous studies in rats by our
group caused us to question this interpretation because we had
shown that, at e18.5, an age when the WD has completely re-
FIG. 5. WD epithelial cell height in male and female rats at e18.5 and in mice at
e16.5. A, Representative images in which the epithelium is immunostained for
cytokeratin. Note that the epithelium appears flatter in control females, but not
in DBP plus F-exposed or ARKO males or in testosterone-treated (T) females,
compared with age-matched control males. Scale bar, 100 m. B, Quantification
of epithelial cell height, demonstrating a significant reduction in control females
compared with males. Note that epithelial cell height is not significantly reduced in
DBP plus F-exposed or ARKO males or in testosterone-exposed females, compared
with control males. Note also that epithelial cell height is significantly different in
WDs from testosterone-treated females compared with control females. ***, P
0.001 compared with control male values; a, P 0.001 compared with control
female values. Values are means SEM for three to six animals per group from at
least two different litters. N/D, Not determined.
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gressed in normal females, WDs recovered from males exposed
in utero to high concentrations of flutamide were comparable to
those from control males (11). However, subsequent differenti-
ation of theWD in these flutamide-exposed males was impaired
by e21.5, and theWD subsequently degenerated during puberty.
These results suggested that eitherWD stabilization can proceed
in males in the presence of lower levels of androgen action than
that required for subsequent differentiation or that WD stabili-
zation is regulated by differentmechanisms to those required for
differentiation. We addressed this issue in the present studies
using rodent models in which fetal androgen action was ablated
inmales or increased in females, and then examined the impact
on WD development, compared with age-matched controls.
These studies demonstrate that testosterone alone can mascu-
linize theWD in females. However, genetic or chemical ablation
of androgenaction inmales doesnot induceWDregressionat the
same time as in normal females, suggesting that there may be
fundamental differences inWDprogramming inmales vs. females,
with factors other than androgens contributing to WD stabiliza-
tion, particularly in the absence of androgen action in males.
Although little is known about the timing of, or mechanisms
underlying, WD regression in females, the majority of under-
standingderives fromstudies in rats (3, 11, 14, 21, 37, 38). In our
rat colony, a patent WD is readily identifiable in female fetuses
at e16.5, but by e18.5 it has almost completely regressed. These
timings agree with previous publications (21, 31, 39). Testos-
terone measurements confirmed that, at e17.5, testosterone was
present in the fetal testis but was barely detectable in the fetal
ovary (12). This agrees with data that plasma testosterone con-
centrations are at least 4-fold lower in female than in male rat
fetuses (4). Conversely, AR protein was detected in WDs from
females whenever a WD was present (data not shown), indicat-
ing that females appear capable of responding to androgens if the
ligand is available. Furthermore, AR protein was immunolocal-
ized to theWDepithelium in females at an agewhen itwas rarely
detected in the epithelium in males (our unpublished data). This
highlights sexually dimorphic expression of AR in the fetal WD,
suggesting that there may be fundamental differences in theWD
in normal males compared with normal females. This difference
in AR expressionmight play a role in the different timing ofWD
regression inmales and females, andmerits further investigation.
Because exposure to high doses of flutamide (100 mg/kg1)
did not induce WD regression in fetal life in male rats (11), we
sought a model in which more complete blockade of androgen
action could be achieved, to determine the dependence of WD
stabilization on androgens alone. Therefore, pregnant rats were
exposed to DBP in combination with flutamide (DBP plus F);
DBP reduces testicular testosterone production in fetal male rats
by 70–90% (15–18, 23, 40, 41), whereas flutamide competes
with residual endogenous androgens for binding to the AR and
so prevents transcriptional activation of AR in target tissues (11,
22, 42, 43). Combined exposure to DBP plus F should result in
a near complete blockade of androgen action and, therefore,
provides a model in which to test if WD stabilization in males is
solely dependent on androgen action.
At e18.5,WDs fromallDBPplus F-exposedmaleswere intact
and had a similar morphology to WDs from control males,
whereasWDregressionwas complete in allmales at e21.5.These
timings contrastwithnormal female rats inwhichWDregression
was nearly complete by e18.5, 2–3 d earlier than in DBP plus
F-exposed males. Because the MD is present in control females
but not in control or DBP plus F-exposed males at e18.5, it is
possible that this could contribute to these differences in the
timing of WD regression. Furthermore, it is possible that DBP
may have a direct effect on theWD, but there is noway of testing
this because it would be impossible to separate any possible di-
rect effect of DBP on the WD from the impact of DBP-induced
reduction in testosterone production. Another obvious explana-
tion for this discrepancy is that DBP plus F still did not result in
complete blockade of androgen action within theWD, but there
is no obvious way to assess this directly. Therefore, to address
this we examinedWD regression in ARKOmice, a rodentmodel
accepted to lack completely a functional AR due to a genetic
mutation (28, 44). InARKOmalemice (n11 litters), as inDBP
plus F-exposed male rats, WD regression is temporally delayed
by approximately 2 d compared with normal littermate females.
We also found similar results in tfmmale mice, in which andro-
gen action is genetically ablated due to a different inactivating
mutation in the AR (n 5 litters; unpublished data). Therefore,
these studies confirmedour findings of delayedWDregression in
males in twodifferent rodent species using three differentmodels
to ablate androgen action.
It is not obvious why the WD should regress slower in males
devoid of androgen action than in normal females, and raises the
question of whether unknown factors could actively promote
WD regression in females or whether factors other than andro-
gens may help maintain the WD in males, particularly in the
absence of androgen action. The precise source of these factors
is unknown; they could be produced by the testis or be endog-
enous to the WD itself. This merits further investigation. How-
ever, this “maintenance” mechanism is clearly not sufficient to
stabilize the WD long term in males because, in both the rat and
mouse models lacking androgen action, the WD ultimately re-
gresses by birth. Thismechanismmight serve to prolong survival
of the WD in males to maximize its opportunity to respond to
testosterone. Further investigations are required to identify the
factor(s) involved, but possible candidates include inhibins
and/or insulin-like factor 3 (Insl3). Body weight is not signifi-
cantly different between that of ARKO or DBP plus F-exposed
males and control females, therefore, we do not believe the dif-
ferences in the timing of WD regression can be explained by
growth rate (unpublished data) (28, 45). Tfm/ARKO mice pro-
vide rodent models for complete androgen insensitivity syn-
drome (CAIS), in which patients are genetically male but have a
female phenotype (46–50).Most evidence fromCAIS patients is
derived frompostnatal examination (51),withnodefinitive pub-
lished evidence on the status of the fetal WD. Therefore, it is
unclearwhether inCAIS patients theWD fails to stabilize during
early fetal life, as occurs in females, or whether the absence of
WD structures in later life results from a “post-stabilization”
degenerationofWD-derived tissues, asoccurs in this study in rats
exposed in utero to DBP plus F and in ARKO male mice.
Because these findings in males question whether androgens
are the only determining factor in WD stabilization, we investi-
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gated the ability of exogenous fetal androgens to stabilize the
WD in females. Exposure to exogenous maternal testosterone in
rats canmasculinize female offspring to varying degrees (25, 39,
52–55).However, some studieswere unable to stabilize theWD,
even in females in which prostates were readily identifiable (25).
In the current study, female reproductive tissues were masculin-
ized by exogenousmaternal testosterone. This is a direct effect of
androgens, rather than due to testosterone being aromatized to
estrogen, because they could be blocked in female fetuses by
combined exposure to testosterone plus flutamide. In our study,
testosterone exposure not only stabilized the WD in all female
rats examined but could even induce some degree of differenti-
ation and compartmentalization, as evidenced by the initiation
of “epididymal” coiling at e21.5. Interestingly, this coiling was
never as pronounced as in control males. It may be that the dose
of testosterone used in this study was not sufficient to fully stim-
ulate coiling, or that thepresenceof thenormalMDalongside the
WD in femalesmayphysically prevent the “stabilized”WDfrom
fully coiling, or that basic differences exist in the WD in females
vs. males that prevent theWD in females from undergoing com-
plete differentiation. Examination of testosterone-exposed fe-
males after birth showed that the stabilized femaleWDpersisted
postnatally and into adulthood, even though exposure to exog-
enous testosterone ceased at birth (data not shown). This sug-
gests that patterning of the fetal WD is established early in re-
productive development (e14.5–e17.5), and, once stabilized, the
female WD persists postnatally. This is in contrast to males ex-
posed to flutamide in utero, in which WD derivatives were
present at birth but were usually absent by adulthood (11). This
contrast further highlights fundamental differences between
males and females, and merits further investigation.
Histological comparison of naturally regressing WDs in fe-
males with those from males deprived of androgen action re-
vealed fundamental differences that support the view that the
WDmaybe subtlydifferent inmales and females. First, apoptosis
was observed in theWDepithelium from control females but not
inWDs from control, ARKO, orDBP plus F-exposedmales or in
testosterone-exposed females. This is in agreementwithprevious
studies in control female rats (5, 21, 56, 57). Second, cell pro-
liferation was not observed in the WD epithelium of control
females but was noted in both the epithelium and mesenchymal
compartments of WDs from control and DBP plus F-exposed
males, and in testosterone-exposed females at e18.5 and in
ARKOmales at e16.5. Third, our results suggest that duringWD
regression in females, epithelial cells lose their attachment to the
basement membrane; these changes may be the trigger for apo-
ptosis (58). Exposure to exogenous testosterone prevented these
WD cellular abnormalities in females. WDs recovered from
e18.5 males exposed to DBP plus F or e16.5 ARKO males
showed no obvious histological abnormalities, whereas around
the time of birth, similar abnormalities were noted to those ob-
served in the regressing female WD at earlier ages. Together,
these data demonstrate differences in the timing of and/or pres-
ence of the cellular processes observed in the WD epithelium in
normal females compared with males. Furthermore, they high-
light that exposure to exogenous testosterone induces “male”
like changes in females but that deprivation of androgen action
(genetically or chemically) cannot induce the cellular changes in
males at the same age as they are seen in control females. These
observations suggest that a similar mechanism for WD degen-
eration is operating in males and females in which androgen
action is absent but that inmales these changesoccur several days
later than in females.
In summary, the present study sought to gain new insight into
WD development by examining the role for androgens in WD
stabilization, rather than in later WD differentiation into its
adult derivatives. These studies have shown that testosterone
alone can stabilize and partially differentiate the WD in females
but that genetically or chemically ablating androgen action in
males does not induce WD degeneration at the same time as it
occurs in females. This suggests either that factors other than
androgens prolong the survival of the WD in males, possibly to
maximize the opportunity for WD stabilization by endogenous
fetal androgens, or that unknown factors actively promote WD
regression in females. Although androgens are critical in WD
stabilization and differentiation, these studies offer the first ev-
idence that they may not be the only factor involved in dictating
the fate of the WD in males. Our studies suggest there are fun-
damental differences in the preprogrammed setup of the WD in
males compared with females and that the differential response
in the fate of the WD may not depend solely on the presence or
absence of androgens.
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